New therapeutic perspectives to manage refractory immune checkpoint-related toxicities-Reference-Cited by-同舟云学术

New therapeutic perspectives to manage refractory immune checkpoint-related toxicities

Published:2019-01 Issue:1 Volume:20 Page:e54-e64
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Martins Filipe,Sykiotis Gerasimos P,Maillard Michel,Fraga Montserrat,Ribi Camillo,Kuntzer Thierry,Michielin Olivier,Peters Solange,Coukos Georges,Spertini Francois,Thompson John A,Obeid Michel

Publisher

Elsevier BV

Subject

Oncology

Reference83 articles.

1. Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma;Kong;Melanoma Res,2016

2. Hemophilia A induced by ipilimumab;Delyon;N Engl J Med,2011

3. Overall survival with combined nivolumab and ipilimumab in advanced melanoma;Wolchok;N Engl J Med,2017

4. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Haanen;Ann Oncol,2017

5. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group;Puzanov;J Immunother Cancer,2017

Cited by 154 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting IL-17A to combat immune-related adverse events;Nature Cancer;2024-08-29

2. Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma;European Journal of Cancer;2024-08

3. Unravelling the Acute, Chronic and Steroid-Refractory Management of High-Grade Neurological Immune-Related Adverse Events: A Call to Action;Brain Sciences;2024-07-29

4. Distinct immune signatures are a potent tool in the clinical management of cytokine-related syndrome during immune checkpoint therapy;2024-07-12

5. Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitors;European Journal of Cancer;2024-05